You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石药(01093.HK)午後升幅扩至11%逼近52周高位交投活跃
阿思达克 05-14 14:28
石药集团(01093.HK)继昨天升至10.24元创逾八个月高位遇压随大市倒跌後,今天股价再探顶,尤其是午後升幅扩大,最高见11.08元,接近去年8月尾所创逾52周高位11.16元,现造10.96元,急涨11%,为最强蓝筹;成交急增至1.27亿股,创两个月高,涉资13.48亿元。

石药日前公布,附属石药集团欧意开发的糖尿病药「苯甲酸阿格列汀片(25mg)」及抗肿瘤药「甲苯磺酸索拉非尼片(0.2g)」均已获中国国家药品监督管理局颁发药品注册批件,并视同通过仿制药质量和疗效一致性评价。此外,该附属开发的葱环类抗生素,属广谱抗肿瘤药的「盐酸多柔比星脂质体注射液(10ml:20mg)」同样已获国家药品监督管理局批准通过仿制药质量和疗效一致性评价,为国内该品种首个通过一致性评价的产品。

恒指高见28,023,现造27,953,回升235点或近0.9%,成交额1,118亿元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account